Skip to main content
Erschienen in: Medical Oncology 3/2014

01.03.2014 | Original Paper

Prostate-specific membrane antigen as a marker of pancreatic cancer cells

verfasst von: He Ren, Huan Zhang, Xiuchao Wang, Junxiu Liu, Zhanna Yuan, Jihui Hao

Erschienen in: Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef
3.
Zurück zum Zitat Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.PubMedCrossRef Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.PubMedCrossRef
4.
Zurück zum Zitat Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef
5.
Zurück zum Zitat Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977–85.PubMed Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977–85.PubMed
6.
Zurück zum Zitat Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547–51.PubMed Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547–51.PubMed
7.
Zurück zum Zitat Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915–8.PubMedCrossRef Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915–8.PubMedCrossRef
8.
Zurück zum Zitat Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRef
9.
Zurück zum Zitat Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471–81.CrossRef Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471–81.CrossRef
11.
Zurück zum Zitat Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.PubMedCrossRef Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.PubMedCrossRef
12.
Zurück zum Zitat Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMed Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMed
13.
Zurück zum Zitat Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205–11.PubMedCrossRef Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205–11.PubMedCrossRef
14.
Zurück zum Zitat McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163–75.CrossRef McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163–75.CrossRef
15.
Zurück zum Zitat Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182–90.PubMedCrossRef Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182–90.PubMedCrossRef
16.
Zurück zum Zitat Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.PubMed Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.PubMed
17.
Zurück zum Zitat Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144–54.PubMedCentralPubMedCrossRef Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144–54.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532–41.PubMedCentralPubMedCrossRef Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532–41.PubMedCentralPubMedCrossRef
Metadaten
Titel
Prostate-specific membrane antigen as a marker of pancreatic cancer cells
verfasst von
He Ren
Huan Zhang
Xiuchao Wang
Junxiu Liu
Zhanna Yuan
Jihui Hao
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0857-z

Weitere Artikel der Ausgabe 3/2014

Medical Oncology 3/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.